ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AbbVie Expands With Singapore Site

by Ann M. Thayer
February 10, 2014 | APPEARED IN VOLUME 92, ISSUE 6

AbbVie will spend $320 million to build a plant in Singapore for small-molecule and biologic active pharmaceutical ingredient manufacturing. The drug company will use the new facility to make oncology and immunology products in its development pipeline. The site will be AbbVie’s first manufacturing location in Asia. It already has about 120 people in Singapore to support commercial operations and R&D, and will add another 250 when the plant is fully operational in 2019. The company also has R&D operations in Tokyo and in Shanghai.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment